PIA
NKTR icon

Piedmont Investment Advisors’s Nektar Therapeutics NKTR Stock Holding History

Piedmont Investment Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,055
Closed -$282K – 469
2020
Q1 		$282K Buy
1,055
+23
+2% +$7.11K 0.01% 626
2019
Q4 		$334K Buy
+1,032
New +$299K 0.01% 702
2019
Q2 		– Sell
-943
Closed -$475K – 1146
2019
Q1 		$475K Buy
943
+19
+2% +$11.3K 0.02% 556
2018
Q4 		$455K Buy
924
+55
+6% +$33.2K 0.02% 492
2018
Q3 		$794K Buy
869
+747
+612% +$638K 0.03% 357
2018
Q2 		$89K Buy
+122
New +$141K ﹤0.01% 1123
2018
Q1 		– Sell
-2,158
Closed -$1.93M – 791
2017
Q4 		$1.93M Sell
2,158
-112
-5% -$66.2K 0.04% 257
2017
Q3 		$817K Buy
2,270
+34
+2% +$10.6K 0.02% 329
2017
Q2 		$656K Buy
2,236
+1,623
+265% +$469K 0.01% 359
2017
Q1 		$216K Buy
+613
New +$138K ﹤0.01% 390

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Piedmont Investment Advisors's NKTR Position: Q2 2020 in Review

Piedmont Investment Advisors sold out of Nektar Therapeutics (NKTR) in Q2 2020, closing a stake of 1,055 shares — an estimated $282K sold.

Piedmont Investment Advisors first reported a position in NKTR in Q1 2017 and held it in 10 quarters. The position peaked at $1.93M in Q4 2017. 260 funds tracked by Wall St. Rank hold NKTR as of Q2 2020.

  • Piedmont Investment Advisors reported no remaining Nektar Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Piedmont Investment Advisors sold 1,055 Nektar Therapeutics shares in Q2 2020, an estimated $282K.
  • Piedmont Investment Advisors first reported a position in Nektar Therapeutics in Q1 2017 and held it in 10 quarters.
  • Piedmont Investment Advisors's Nektar Therapeutics position peaked at $1.93M in Q4 2017.
  • 260 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2020.

Based on Piedmont Investment Advisors's 13F filing for Q2 2020.